Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 17;13:837680. doi: 10.3389/fphar.2022.837680

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Seeliger, Carleo, Wendel-Garcia, Fuge, Montes-Warboys, Schuchardt, Molina-Molina and Prasse.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Changes in longitudinal analysis before vs. after initiation of antifibrotic treatment with nintedanib. Log2-Fold changes were plotted against -log10 (p-value) of cohort 1 (A) and cohort 2 (B) as volcano-plots with numbers of significantly (FDR<0.05) up or down-regulated analytes indicated (sample after treatment vs. baseline). The deregulated analytes in both cohorts are shown in (C), with no overlap between the cohorts. Delta-values (sample after treatment vs. baseline) of cohort 1 were calculated per patient and changes between the de-regulated analytes were plotted via heat-map with hierarchical clustering (ward.D method) (D). The resulting patient clusters were then compared via Kaplan-Meier curves and adjusted cox-regression modelling (for GAP-index) (E).